Clinical trials: Squamous Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than…
- Trial name
- NCT01160744
- Testing
- IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6)
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
This randomized phase II trial studies how well pemetrexed disodium with or without crizotinib works in treating patients with stage IV non-small cell lung cancer that has progressed after crizotinib.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT02134912
- Testing
- crizotinib, pemetrexed disodium, laboratory biomarker analysis
- Where
- 167 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Advanced Solid Tumor, Cutaneous Tumor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed…
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
- Trial name
- ANCHOR (NCT06171750)
- Testing
- tolododekin alfa, Cemiplimab
- Where
- 5 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Ankyra Therapeutics, Inc
NSCLC Stage IV, KRAS Gene Mutation
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small…
- Conditions
- NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody, Chemotherapy Effect
- Trial name
- NCT03777124
- Testing
- SHR-1210, Apatinib, Pemetrexed
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small-Cell Lung Carcinoma
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred…
- Trial name
- NCT00404924
- Testing
- ZD6474 (vandetanib), Best Supportive Care
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 1,140 people
- Sponsor
- Genzyme, a Sanofi Company
Melanoma, Breast Cancer
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy.
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer
- Trial name
- AM-003 (NCT04116320)
- Testing
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Craig L Slingluff, Jr
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non-Small Cell Lung Cancer
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of bevacizumab (Avastin) versus placebo in combination with carboplatin/paclitaxel in participants with advanced or recurrent…
- Trial name
- NCT01364012
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 17 sites in China
- Volunteers
- 276 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
- Trial name
- NCT07489066
- Testing
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
ALK-positive Non Small Cell Lung Cancer
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
This is a single-arm clinical study planning to enroll 30 treatment-naive patients with resectable ALK-positive non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07771764
- Testing
- iruplaltinib and pemetrexed
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Non-Small-Cell Lung Cancer
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based…
- Trial name
- KANNON-5 (NCT07336732)
- Testing
- PLB1004
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
- Trial name
- iNUDGE (NCT05853887)
- Testing
- iNUDGE
- Where
- 6 sites in United States
- Volunteers
- 260 people
- Sponsor
- Charu Aggarwal
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies the effect of bintrafusp alfa with pemetrexed and platinum-based chemotherapy (carboplatin or cisplatin) in treating patients with EGFR mutant non-small cell lung cancer that have spread to nearby…
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT04971187
- Testing
- Bintrafusp Alfa, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT07662811
- Testing
- SYHX2011, Carboplatin, Enlonstobart
- Volunteers
- 396 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer
The number of NSCLC patients above 70 years of age who are non-squamous histology is increasing around the world. Although previous guidelines often recommend single agent therapy for NSCLC, recent studies suggest that platinum…
- Trial name
- ACE (NCT01593293)
- Testing
- PemCarbo, Pem only
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- Asan Medical Center
Non-Small Cell Lung Cancer Metastatic
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer.
- Trial name
- STAGGER (NCT04163432)
- Testing
- Durvalumab, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Squamous NSCLC
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
The study consists of two parts: Part I is a randomized, double-blind, multicenter, parallel-controlled phase II clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus…
- Trial name
- NCT07318883
- Testing
- HLX07, Serplulimab, Pembrolizumab
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Shanghai Henlius Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.